# Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis

> **NCT03091439** · PHASE2 · TERMINATED · sponsor: **Allergan** · enrollment: 1 (actual)

## Conditions studied

- Osteomyelitis

## Interventions

- **DRUG:** Dalbavancin
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT03091439
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-15
- **Primary completion:** 2017-08-31
- **Final completion:** 2017-08-31
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Business decision outlined by the corporation.
- **Last updated:** 2018-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03091439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03091439, "Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03091439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*